Issuu

ExchangeCME.com/ CRSwNPLosAngelesCRC This activity is provided by Integritas Communications. This activity is supported by an educational grant from AstraZeneca. This program is not sponsored or programmed by AAO-HNSF. The content and opinions expressed are those of the sponsor and/or presenter(s) and are not necessarily those of AAO-HNSF. There is no fee to attend this educational program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

GET FREE ACCESS TO THE LATEST CME/CE ACTIVITIES, WEBINARS, EVENTS, AND MORE AT EXCHANGECME.COM.

Subscribe to our YouTube channel @exchangecme for additional informative videos. youtube.com/c/ExchangeCME

MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com

FACULTY Joseph K. Han, MD, FARS, FAAAAI FACULTY

Professor of Otolaryngology Vice Chair of Clinical Affairs and Administration Past Chief, Division of Rhinology and Endoscopic Sinus and Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Old Dominion University Norfolk, Virginia

Dr. Joseph Han is the Past Chief for the Division of Rhinology & Endoscopic Sinus and Skull Base Surgery, as well as the Chief for the Division of Allergy. Dr. Han holds a Bachelor of Science degree from University of Washington, a Medical Degree from the Medical College of Pennsylvania, and completed an Otolaryngology-Head & Neck Surgery residency at the Medical College of Wisconsin and completed a fellowship in Rhinology at Oregon Health Sciences University. Dr. Han has received numerous awards including Best Doctors of America and Top Doctors by US News & Report. Dr. Joseph Han is a national and international leader in rhinology, allergy, and endoscopic skull base surgery. He is currently the President of the American Rhinologic Society. He was president of the American Rhinologic Society (ARS), Virginia Society of Otolaryngology, Tidewater Otolaryngology & Ophthalmology Society, and Korean American Otolaryngology Society and chair of the Rhinology and Paranasal Sinus Committee for the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS). He is chair of the Rhinitis, Rhinosinusitis, and Ocular Allergy Committee for the American Academy of Allergy, Asthma & Immunology. Dr. Han was an associate editor for two scientific journals and is currently on the editorial board for the International Forum of Allergy and Rhinology. Dr. Han is currently a guest examiner for the American Board of Otolaryngology – Head and Neck Surgery. Dr. Han is Editor of Practical Medical and Surgical Management of Chronic Rhinosinusitis and a Section Editor of Ballenger’s Otolaryngology: Head and Neck Surgery. He was involved in the AAO-HNS Guidelines Task Force. He has more than 100 scientific publications, 175 national and international scientific presentations, and 150 guest lectureships. Dr. Han is very active in both basic science research as well as clinical research studies. His thesis was on subclassification of chronic rhinosinusitis (CRS), endotyping and phenotyping CRS. He has been awarded NIH funding for the study of chronic sinusitis and has been the lead investigators for several multi-national, multi-institutional, prospective clinical trials on chronic sinusitis and nasal polyposis including the use of biologics for nasal polyps. His clinical interests include allergies, nasal obstruction, sinusitis, cerebrospinal fluid leakage, and nasal/skull base tumors. He is one of the pioneers for endoscopic skull base surgery.

Rohit K. Katial, MD FACULTY

Professor of Medicine Division of Allergy & Clinical Immunology Associate Vice President of Clinical Research & Industry Relationships Co-Director of the Asthma Institute at National Jewish Health Helen Wohlberg & Herman Lambert Chair National Jewish Health Mount Sinai Respiratory Institute Denver, Colorado

Dr. Rohit Katial is Professor of Medicine at National Jewish Health and the University of Colorado in Denver. He received his MD at Georgetown University School of Medicine, and conducted fellowship at Fitzsimons Army Medical Center, National Jewish Health, and Walter Reed Army Medical Center. He is the current Program Director and has been on the ABAI and ACGME. He is ABIM and the ABAI certified. He is a Fellow of the ACAAI, AAAAI, and ACP. He has published extensively and has received numerous commendations for his clinical expertise, including being named to Denver’s Top Doctors for numerous consecutive years.

Stella Lee, MD FACULTY

Associate Professor of Otolaryngology–Head and Neck Surgery Harvard Medical School Section Chief – Rhinology Director, Brigham Sinus Center Brigham and Women’s Hospital Boston, Massachusetts

Dr. Stella Lee is a fellowship-trained rhinologist and director of the Brigham Sinus Center. She is board certified by the American Board of Otolaryngology – Head and Neck Surgery. Her holistic and evidence-based approach seeks to understand the cause of symptoms in order to best treat the underlying disease process and improve the quality of life of her patients. Dr. Lee is experienced in the comprehensive medical and surgical management of patients with sinonasal and skull base disorders including nasal obstruction, smell loss, sinusitis, nasal polyps, allergic rhinitis, tumors of the sinuses, nose, and skull base as well as the treatment of patients with cystic fibrosis and hereditary hemorrhagic telangiectasia. Her philosophy is to provide multidisciplinary care with experts in the field to achieve the best outcome possible for her patients. Dr. Lee earned her Bachelor of Science degree in Neuroscience from Duke University in Durham, North Carolina, before attending the Rosalind Franklin University of Medicine and Science in Chicago, Illinois. She completed her residency in Otolaryngology–Head and Neck Surgery at Yale University in New Haven, Connecticut, followed by a fellowship in Rhinology and Skull Base Surgery at Johns Hopkins University in Baltimore, Maryland. Before joining the Brigham faculty, Dr. Lee served as the Division Chief for Sinonasal Disorders and Allergy in the Department of Otolaryngology at the University of Pittsburgh Medical Center in Pennsylvania for 10 years. Her research interests include understanding the inflammatory endotypes of chronic rhinosinusitis, olfactory dysfunction, the impact of environmental pollution on airway inflammation, and development of basic to translational strategies to solve chronic inflammation (www.solvecrs.com). She is a leader in the development of novel therapeutics and creation of new paradigms of how we conceptualize and treat sinus and skull base disorders.

PROGRAM OVERVIEW

PREAMBLE

Please join us for dinner and a dynamic Science in the Spotlight symposium featuring expert panelists Drs. Joseph Han, Stella Lee, and Rohit Katial as they examine evolving management approaches for chronic rhinosinusitis with nasal polyps (CRSwNP), with a focus on biologics targeting epithelial-derived cytokines in the airways, including thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33). This program brings together perspectives from allergy, immunology, and otorhinolaryngology to explore how these epithelial alarmins drive the inflammation, airway dysfunction, and disease persistence seen in patients with CRSwNP. Through a focused Whiteboard animation, case-based checkpoints, and interactive faculty dialogue, the engaging, multidisciplinary faculty panel will guide participants through both an examination of epithelial cytokine signaling in CRSwNP and practical therapeutic decision-making involving new and emerging biologic therapies that target alarmin cytokines. In addition, attendees will also learn about the latest clinical evidence for newer and emerging biologic therapies targeting epithelial alarmin-driven inflammation and discuss how to incorporate these novel therapies into mechanism-based treatment strategies, with an emphasis on optimizing disease control, escalating treatment as needed, reducing the need for oral corticosteroids and endoscopic sinus surgery, reducing symptom burden, and improving the quality of life experienced by patients living with CRSwNP.

TARGET AUDIENCE This educational activity has been designed to educate ear, nose, and throat (ENT) specialists, clinical immunologists/allergists, and pulmonologists who manage patients with CRSwNP.

LEARNING OBJECTIVES Upon completion of this activity, participants should be better able to: • Describe the roles of epithelial cytokine signaling in the pathogenesis of CRSwNP, including implications for patient evaluations and treatment • Assess patients with CRSwNP for symptom burden, psychosocial effects, comorbidities, and treatment responses • Discuss the clinical profiles and evidence for biologic therapies that target epithelial cytokines in the treatment of CRSwNP • Escalate treatment appropriately for CRSwNP to address underlying pathophysiologic processes, improve disease control, and reduce the need for oral corticosteroids or endoscopic sinus surgery

PROGRAM AGENDA 6:00 pm Preactivity Questionnaire and Faculty Introductions 6:10 pm

Early Signaling in CRSwNP

6:30 pm

Comprehensively Evaluating Patients With CRSwNP

6:45 pm Evolving Management of CRSwNP 7:15 pm Key Takeaways, Recap, Postactivity Questionnaire, and Q&A Session

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS TO RECEIVE CREDIT In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation.

DISCLOSURES OF CONFLICTS OF INTEREST Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies: Joseph Han, MD: Consulting Fees: AstraZeneca plc, GSK plc, Regeneron Pharmaceuticals, Inc., Sanofi

PREAMBLE

PHYSICIAN ACCREDITATION STATEMENT

Rohit K. Katial, MD: Consulting Fees: AstraZeneca plc, Grifols, GSK plc, SanofiRegeneron, Novartis; Speakers’ Bureau: AstraZeneca plc Stella Lee, MD: Consulting Fees: AstraZeneca plc, Genentech, GSK plc, Lyra Therapeutics, OptiNose, Sanofi-Regeneron The Integritas planners and managers have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

PREAMBLE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION & REFUND/ CANCELLATION POLICY There is no fee for this activity.

AMERICANS WITH DISABILITIES ACT Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas at info@exchangecme.com to discuss their specific needs.

INTEGRITAS CONTACT INFORMATION For information about this program, please contact us at info@exchangecme.com.

SLIDES

CLINICAL PRACTICE GUIDELINES

» EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Fokkens WJ, et al. Rhinology. 2023;61(3):194-202. https://www.rhinologyjournal.com/download.php?id=3069

» European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Fokkens WJ, et al. Rhinology. 2020;58(Suppl S29):1-464. https://www.rhinologyjournal.com/Documents/Supplements/ supplement_29.pdf

PATIENT-REPORTED OUTCOMES MEASURES (PROM)

» Sino-Nasal Outcome Test-22 (SNOT-22)

https://river-ent.com/wp-content/uploads/2020/10/Form-SNOT-22-SinoNasal.pdf

» Evaluation of the Patient Global Impression of Symptom Severity (PGISS) Score as a Subjective and Objective Measure of Disease Activity in Chronic Rhinosinusitis. Lim Set al. Am J Rhinol Allergy. 2025;39(2):128-135. https://journals.sagepub.com/doi/10.1177/19458924241312318?url_ ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed